MOGAD Treatment
Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) presents unique challenges that distinguish it from both MS and AQP4-NMOSD management. The key considerations include: (1) approximately 50% of patients have a monophasic course, making the decision of whom and when to treat more complex; (2) no drugs are currently FDA-approved specifically for MOGAD relapse prevention; (3) steroid-dependent recrudescence is a common phenomenon requiring prolonged oral tapers; and (4) MS therapies should be avoided. Treatment decisions must be individualized based on attack severity, degree of recovery, relapse history, and serial MOG-IgG titer monitoring.
Bottom Line
- Acute treatment: IV methylprednisolone 1 g/day × 5–7 days followed by a prolonged oral prednisone taper to prevent steroid-dependent recrudescence
- PLEX: Consider early for severe attacks, same as AQP4-NMOSD; do not wait for antibody results
- Maintenance decision: ~50% are monophasic — if complete recovery from first attack, may wait for second attack before starting long-term treatment
- IVIg: Emerging as a key maintenance option, especially in pediatric patients; avoids immunosuppression-related risks
- MOG-IgG titer monitoring: Seroconversion to negative reduces relapse risk; persistent positivity favors relapsing course
- No FDA-approved maintenance therapy yet: Fc receptor inhibitors (rozanolixizumab) and IL-6 blockers under clinical evaluation
- MS DMTs are ineffective and potentially harmful: Interferon-beta, fingolimod, natalizumab, and glatiramer should not be used
Acute Treatment
High-Dose Corticosteroids
As in AQP4-NMOSD, high-dose IV corticosteroids are the first-line treatment for acute MOGAD attacks. However, MOGAD has a unique propensity for steroid-dependent recrudescence — worsening of symptoms upon steroid withdrawal or rapid taper.
MOGAD Acute Treatment Protocol
- IV methylprednisolone 1 g/day for 5–7 days
- Followed by oral prednisone taper:
- Start at 1 mg/kg/day (or 50–75 mg/day)
- Maintain full dose for a few weeks up to 12 weeks
- Slow taper: 5 mg reduction every 2 weeks until withdrawal
- Total oral taper duration may be 3–6 months
- Alternatively, some clinicians omit the oral taper given that most patients will not have an early relapse and prolonged corticosteroid use carries significant morbidity (particularly in children)
Steroid Recrudescence in MOGAD
A taper with oral corticosteroids after the acute treatment of MOGAD attacks is recommended to avoid symptom recrudescence that occurs specifically with this disease upon steroid waning or withdrawal. This phenomenon is characteristic of MOGAD and is less common in MS or AQP4-NMOSD. If symptoms worsen during taper, consider increasing the dose and slowing the taper rate, and initiate discussions about long-term immunosuppression.
Plasma Exchange (PLEX)
- Same regimen as for NMOSD: 5–7 sessions on alternate days, concurrent with corticosteroids
- Consider early initiation (day 3–4) for severe attacks with significant disability, regardless of antibody serostatus
- Evidence for benefit comes from the pivotal 1999 randomized, sham-controlled trial that predated the discovery of MOG antibodies
Intravenous Immunoglobulin (IVIg) for Acute Attacks
- Dosing: 0.4 g/kg/day for 5 consecutive days
- May be considered for incomplete recovery after corticosteroids and PLEX
- Can be protracted as maintenance therapy (see below)
- More commonly used in children with MOGAD
Rescue Therapies
For rare cases refractory to corticosteroids, PLEX, and IVIg:
- IL-6 receptor inhibitors (e.g., tocilizumab) — expected rapid response
- Cyclophosphamide — expected rapid response
- Autologous HSCT — reported improvement in super-refractory cases
- B-cell depleting agents (rituximab) may require longer to become effective
Maintenance Therapy Decision-Making
The decision about long-term relapse prevention in MOGAD is considerably more nuanced than in AQP4-NMOSD, where maintenance therapy is universally indicated. The key challenge: only ~50% of MOGAD patients will relapse, and most patients recover well from individual attacks.
Approach After First Attack
| Scenario | Approach | Rationale |
|---|---|---|
| Complete recovery, first attack | Monitor without maintenance therapy; wait for second attack before starting immunosuppression | ~50% will have monophasic disease; unnecessary chronic treatment avoided |
| Incomplete recovery, first attack | Consider early initiation of maintenance therapy | Further disability from a second attack in the setting of incomplete recovery could be devastating |
| Second confirmed attack | Initiate maintenance therapy | Establishes relapsing phenotype; ongoing relapse prevention warranted |
| Severe first attack (e.g., bilateral ON, respiratory failure) | Consider maintenance therapy even with good recovery | Severity of potential recurrence warrants prevention |
Serial MOG-IgG Titer Monitoring
Utility of Serial Antibody Testing
- Periodic measurements of MOG-IgG titer can inform treatment decisions
- Seroconversion to negative significantly reduces the risk of future relapses
- Persistent seropositivity (especially rising titers) is associated with higher relapse risk
- Consider retesting every 6–12 months during the monitoring period after a first attack
- A patient who seroreverts may be reassured about lower relapse risk, though continued clinical vigilance remains appropriate
Maintenance Treatment Options
No drugs are currently FDA-approved for relapse prevention in MOGAD, though several are under clinical evaluation. Available options are based on retrospective data and clinical experience.
Intravenous Immunoglobulin (IVIg) Maintenance
IVIg has shown the most consistent promise for MOGAD relapse prevention in retrospective studies:
| Parameter | Detail |
|---|---|
| Loading dose | 0.4 g/kg/day × 5 days |
| Maintenance dose | 0.4–2 g/kg monthly (commonly 1 g/kg) |
| Route | Intravenous (subcutaneous immunoglobulin is an alternative) |
| Key advantages | Not immunosuppressive; suitable for children and patients at high infection risk |
| Limitations | Costly; requires regular infusions; headache and hypertension during infusions |
IVIg is a particularly reasonable option for pediatric patients with MOGAD or patients with a higher risk of infections for whom avoiding immunosuppression is preferable.
Rituximab (Anti-CD20)
- Initially shown to be less effective in MOGAD compared with AQP4-NMOSD
- More recent data (2023) suggest similar effectiveness when comparing patients with similar annualized relapse rates
- Dosing same as for AQP4-NMOSD: induction with 1 g × 2 (2 weeks apart) or 375 mg/m² weekly × 4, then reinfusion at 6-month intervals or based on B-cell reconstitution
- Mechanism may be incomplete given that MOG-IgG-producing cells include CD20-negative plasmablasts
Oral Immunosuppressants
- Azathioprine: Moderately effective; requires 3–6 months to achieve full effect; bridge with oral corticosteroids
- Mycophenolate mofetil: Similar efficacy profile to azathioprine; also requires bridging therapy
- Can be considered when IVIg or biologic agents are unavailable
Tocilizumab (Anti-IL-6 Receptor)
- IV 8 mg/kg every 4 weeks
- Appeared safe and potentially effective in MOGAD based on retrospective observational data
- Prospective RCT data in MOGAD not yet available
Drugs Under Clinical Development for MOGAD
| Drug/Class | Mechanism | Status |
|---|---|---|
| Rozanolixizumab | Neonatal Fc receptor (FcRn) inhibitor | Clinical trial ongoing for relapse prevention in MOGAD |
| Satralizumab | Anti-IL-6 receptor | Currently being studied for MOGAD (already FDA-approved for AQP4-NMOSD) |
| Other FcRn inhibitors | Reduce pathogenic IgG levels by blocking neonatal Fc receptor recycling | In development |
| Other IL-6 pathway agents | Target IL-6 signaling pathway | In development |
FcRn inhibitors are particularly promising for MOGAD given the antibody-mediated pathophysiology — by reducing total IgG levels (including pathogenic MOG-IgG), these drugs may directly address the disease mechanism.
Treatment Comparison: MOGAD vs. AQP4-NMOSD
| Feature | MOGAD | AQP4-NMOSD |
|---|---|---|
| Maintenance urgency | Individualized; may wait for second attack | Immediate; nearly universal relapse risk |
| FDA-approved options | None | Satralizumab, inebilizumab, eculizumab |
| Oral steroid taper | Recommended (steroid recrudescence common) | Not routinely required |
| IVIg role | Prominent (both acute and maintenance) | Limited (mainly acute rescue) |
| Rituximab efficacy | Variable; may be less effective | ~60–70% effective |
| Complement inhibitors | Not studied | Highly effective |
| Serial antibody monitoring | Informative (seroconversion reduces risk) | Less informative for treatment decisions |
Therapies to Avoid in MOGAD
- MS disease-modifying therapies are not effective for MOGAD and may be harmful
- Interferon-beta, fingolimod, natalizumab, and glatiramer acetate should not be used
- Accurate differentiation of MOGAD from MS is essential before initiating treatment
- If a patient initially diagnosed with MS is found to have MOG-IgG positivity with compatible clinical-MRI features, the treatment approach should be revised
Pregnancy Considerations
- MOGAD can relapse during pregnancy or postpartum
- Treatment decisions require individualized risk-benefit discussions
- IVIg may be a preferred maintenance option during pregnancy (generally considered safe)
- Rituximab and most oral immunosuppressants should be discontinued with appropriate washout periods before conception
- Corticosteroids can be used for acute attacks during pregnancy
Monitoring and Follow-Up
Recommended Monitoring Strategy
- Clinical assessment: Regular neurological examination every 3–6 months
- MRI: Brain and spinal cord MRI at 6–12 months after attack, then annually or as clinically indicated
- MOG-IgG titer: Every 6–12 months; seroconversion may inform decisions about treatment duration
- Visual assessment: OCT and visual acuity testing for patients with optic neuritis history
- Laboratory monitoring: As indicated by specific therapy (CBC, liver function for oral immunosuppressants; immunoglobulin levels for B-cell depleting agents)
References
- Sechi E. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease. Continuum (Minneap Minn). 2024;30(4):1057-1090.
- Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023;22(3):268-282.
- Sechi E, Cacciaguerra L, Chen JJ, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management. Front Neurol. 2022;13:885218.
- Ringelstein M, Ayzenberg I, Lindenblatt G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm. 2022;9(1):e1100.
- Chen JJ, Flanagan EP, Jitprapaikulsan J. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8-15.